NXS 6.67% 24.0¢ next science limited

Non-sponsored medical literature? I can't comment on the quality...

  1. 24 Posts.
    lightbulb Created with Sketch. 10
    Non-sponsored medical literature?

    I can't comment on the quality of evidence or possible bias of the research but it's worth noting that the founder and CTO, with a share holding of almost $50M at today's valuation, is the lead or contributing author on almost all studies involving the technology.
 
watchlist Created with Sketch. Add NXS (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.